MIDDLE EAST AND TURKEY IMMUNE THROMBOCYTOPENIC PURPURA (ITP) TREATMENT DRUGS MARKET ANALYSIS

Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, by Drug Type (Steroid, Immunoglobulins, Thrombopoietin Receptor Agonist and Others, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and By Country (Turkey, Israel, Egypt, Saudi Arabia, UAE, and Rest of Middle East) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Dec 2019
Code : CMI3171
Pages :114
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market - Restraints

To treat ITP, alternative surgical procedures such as splenectomy and bone marrow transplant are often the choice of treatment because of better outcomes. These factors are expected to hamper growth of the Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market over the forecast period. For instance, according to data published by Al-Aqsa University Journal in January 2017, Splenectomy cures ITP by removing both the primary site of platelet destruction and an important site of antiplatelet antibody production in a large proportion of patients. According to the same source, laparoscopic splenectomy has recorded a success rate of 72% at 5 years. Sustained responses were observed in 60–80% of ITP patients undergoing splenectomy in 2017.

Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market Report Snapshots